Jordy van Enkhuizen1, Mark A Geyer2, Adam L Halberstadt3, Xiaoxi Zhuang4, Jared W Young5. 1. Department of Psychiatry, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA 92093-0804, United States; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. 2. Department of Psychiatry, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA 92093-0804, United States; Research Service, VA San Diego Healthcare System, San Diego, CA, United States. 3. Department of Psychiatry, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA 92093-0804, United States. 4. Department of Neurobiology, University of Chicago, Chicago, IL, United States. 5. Department of Psychiatry, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA 92093-0804, United States; Research Service, VA San Diego Healthcare System, San Diego, CA, United States. Electronic address: jaredyoung@ucsd.edu.
Abstract
BACKGROUND: Patients with BD suffer from multifaceted symptoms, including hyperactive and psychomotor agitated behaviors. Previously, we quantified hyperactivity, increased exploration, and straighter movements of patients with BD mania in the human Behavioral Pattern Monitor (BPM). A similar BPM profile is observed in mice that are hyperdopaminergic due to reduced dopamine transporter (DAT) functioning. We hypothesized that dopamine depletion through alpha-methyl-p-tyrosine (AMPT) administration would attenuate this mania-like profile. METHODS: Male and female DAT wild-type (WT; n=26) and knockdown (KD; n=28) mice on a C57BL/6 background were repeatedly tested in the BPM to assess profile robustness and stability. The optimal AMPT dose was identified by treating male C57BL/6 mice (n=39) with vehicle or AMPT (10, 30, or 100mg/kg) at 24, 20, and 4h prior to testing in the BPM. Then, male and female DAT WT (n=40) and KD (n=37) mice were tested in the BPM after vehicle or AMPT (30mg/kg) treatment. RESULTS: Compared to WT littermates, KD mice exhibited increased activity, exploration, straighter movement, and disorganized behavior. AMPT-treatment reduced hyperactivity and increased path organization, but potentiated specific exploration in KD mice without affecting WT mice. LIMITATIONS: AMPT is not specific to dopamine and also depletes norepinephrine. CONCLUSIONS: KD mice exhibit abnormal exploration in the BPM similar to patients with BD mania. AMPT-induced dopamine depletion attenuated some, but potentiated other, aspects of this mania-like profile in mice. Future studies should extend these findings into other aspects of mania to determine the suitability of AMPT as a treatment for BD mania.
BACKGROUND:Patients with BD suffer from multifaceted symptoms, including hyperactive and psychomotor agitated behaviors. Previously, we quantified hyperactivity, increased exploration, and straighter movements of patients with BD mania in the human Behavioral Pattern Monitor (BPM). A similar BPM profile is observed in mice that are hyperdopaminergic due to reduced dopamine transporter (DAT) functioning. We hypothesized that dopamine depletion through alpha-methyl-p-tyrosine (AMPT) administration would attenuate this mania-like profile. METHODS: Male and female DAT wild-type (WT; n=26) and knockdown (KD; n=28) mice on a C57BL/6 background were repeatedly tested in the BPM to assess profile robustness and stability. The optimal AMPT dose was identified by treating male C57BL/6 mice (n=39) with vehicle or AMPT (10, 30, or 100mg/kg) at 24, 20, and 4h prior to testing in the BPM. Then, male and female DAT WT (n=40) and KD (n=37) mice were tested in the BPM after vehicle or AMPT (30mg/kg) treatment. RESULTS: Compared to WT littermates, KD mice exhibited increased activity, exploration, straighter movement, and disorganized behavior. AMPT-treatment reduced hyperactivity and increased path organization, but potentiated specific exploration in KD mice without affecting WT mice. LIMITATIONS: AMPT is not specific to dopamine and also depletes norepinephrine. CONCLUSIONS: KD mice exhibit abnormal exploration in the BPM similar to patients with BD mania. AMPT-induced dopamine depletion attenuated some, but potentiated other, aspects of this mania-like profile in mice. Future studies should extend these findings into other aspects of mania to determine the suitability of AMPT as a treatment for BD mania.
Authors: Jagadeesh Sridhara Rao; Matthew Kellom; Edmund Arthur Reese; Stanley Isaac Rapoport; Hyung-Wook Kim Journal: J Affect Disord Date: 2011-09-16 Impact factor: 4.839
Authors: Anabel Martínez-Arán; Eduard Vieta; María Reinares; Francesc Colom; Carla Torrent; Jose Sánchez-Moreno; Antonio Benabarre; José Manuel Goikolea; Mercè Comes; Manel Salamero Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112
Authors: Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-08-19 Impact factor: 8.989
Authors: Morgane Milienne-Petiot; James P Kesby; Mary Graves; Jordy van Enkhuizen; Svetlana Semenova; Arpi Minassian; Athina Markou; Mark A Geyer; Jared W Young Journal: Neuropharmacology Date: 2016-10-11 Impact factor: 5.250
Authors: Jordy van Enkhuizen; David S Janowsky; Berend Olivier; Arpi Minassian; William Perry; Jared W Young; Mark A Geyer Journal: Eur J Pharmacol Date: 2014-08-05 Impact factor: 4.432
Authors: Marc A Mergy; Raajaram Gowrishankar; Paul J Gresch; Stephanie C Gantz; John Williams; Gwynne L Davis; C Austin Wheeler; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely Journal: Proc Natl Acad Sci U S A Date: 2014-10-20 Impact factor: 11.205